MO

AI Research

UBS raises PT to $74 + ZYN pouches FDA approved → MO nicotine transition gains

Altria Group received a boost from UBS raising its price target to $74, citing the successful oral nicotine transition strategy as ZYN nicotine pouches received full FDA marketing authorization, validating the company's pivot away from combustible cigarettes. The company declared its quarterly dividend of $1.06 per share, yielding approximately 7.5%, maintaining its appeal as an income stock in uncertain markets. Risks include continued cigarette volume declines accelerating beyond guidance and potential FDA regulatory actions on flavored oral nicotine products that could impact ZYN's growth trajectory.